Prevalence of Mismatch Repair Gene Defects by Means of Immuno-histochemistry Staining for MMR Proteins in Endometrial Cancer
- PMID: 40390959
- PMCID: PMC12085453
- DOI: 10.1007/s13224-024-02034-z
Prevalence of Mismatch Repair Gene Defects by Means of Immuno-histochemistry Staining for MMR Proteins in Endometrial Cancer
Abstract
Introduction: In India, the incidence of uterine cancer is 17,420 per year. Presence of mismatch repair genes is one of the risk factors which can cause microsatellite instability in DNA leading to hereditary syndromes as well as sporadic cancer. In the present study, we aim to determine the prevalence of MMR gene mutations by IHC staining for MMR proteins in endometrial cancer. We further aim to corelate various clinic-pathological features with mismatch repair gene defect (MMRd) cancers and to determine its effects recurrence and survival in endometrial cancer.
Materials and methods: This is an ambispective study of a retrospectively selected cohort followed up prospectively. It was conducted in the Department of Gynaecological Oncology, AIMS. The cohort was evaluated for the four MMR proteins via IHC staining, and their various clinic-pathological factors were studied. Also, the factors affecting their recurrence free survival (RFS) and overall survival (OS) were observed.
Results: The prevalence of MMR loss in endometrial cancer patients was 31.34%. Most common loss of MMR gene was MLH1 and PMS 2 (57.14%). We did not find any significant differences pertaining to age, BMI, menstrual status, family history and second malignancies in both groups of endometrial cancers. While comparing the histopathological characteristics, no significant difference was found regarding to histopathology, stage, type, grade, P53 status, tumour size, lymph node involvement and LVSI status. No significant difference was seen between two groups in RFS and OS.
Conclusion: We found a significant proportion of endometrial cancers with defective MMR genes in Indian population. We did not find any correlation of MMR to the various clinical and histopathological factors that we analysed. MMRd did not significantly affect the RFS and OS in endometrial cancers.
Keywords: Endometrial cancer; MMR gene defect; Mismatch repair proteins; Molecular classification of uterine cancer; Uterine cancer.
© Crown 2024.
Conflict of interest statement
Conflict of interestAuthors have no conflict of interest.
Similar articles
-
Second malignancies in patients with deficient mismatch repair system/microsatellite instability-high colorectal cancer.Therap Adv Gastroenterol. 2025 Jun 21;18:17562848251347375. doi: 10.1177/17562848251347375. eCollection 2025. Therap Adv Gastroenterol. 2025. PMID: 40547253 Free PMC article.
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
References
-
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. - PubMed
-
- Cancer Today [Internet]. [cited 2019 Dec 29]. Available from: https://gco.iarc.fr/today/home
-
- Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12–39. - PubMed
LinkOut - more resources
Research Materials
Miscellaneous